Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boost for biosimilar switching as Finns add their backing

This article was originally published in Scrip

Executive Summary

Finland's Fimea has become the latest national regulatory agency in the EU to issue a formal statement supporting the switching of patients from a reference biological product to a biosimilar version – and vice versa – on the grounds that there is no evidence that doing so causes any adverse effects.

You may also be interested in...



EMA Suspends Leo’s Actinic Keratosis Drug Picato

The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.

Australian Fees To Rise As Drug Registrations Decline

The Therapeutic Goods Administration says that its cost-recovery fees need to go up, mainly because of a fall in the number of medicines on the therapeutic products register. It is also seeing a rise in the cost of the fee-free services it provides.

Australian Fees To Rise As Registrations Decline

The Therapeutic Goods Administration says that its cost-recovery fees need to go up, mainly because of a fall in the number of products on the therapeutic products register. It is also seeing a rise in the cost of the fee-free services it provides.

Topics

UsernamePublicRestriction

Register

SC028812

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel